Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04626635 |
TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2020-11-12 |
地点
California, United States
Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States 法国 以色列 荷兰 波兰 西班牙 Turkey |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
cemiplimab, REGN7075 |
标签
MSS/ MMRp
|
| NCT ID NCT01174121 |
Title利用肿瘤浸润淋巴细胞为转移性癌症患者提供免疫疗法 | 阶段
第二阶段
|
Date Added 2010-08-03 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05107674 |
TitleA Study of NX-1607 in Adults With Advanced Malignancies | 阶段
第 1 阶段
|
Date Added 2021-11-04 |
地点
California, United States
Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
NX-1607 |
标签
MSS/ MMRp
|
| NCT ID NCT02693535 |
TitleTAPUR：测试食品药品管理局（FDA）批准的针对晚期癌症患者肿瘤基因特定异常的药物的使用情况 | 阶段
第二阶段
|
Date Added 2016-02-26 |
地点
Alabama, United States
Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04111458 |
TitleA Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | 阶段
第 1 阶段
|
Date Added 2019-10-01 |
地点
Massachusetts, United States
North Carolina, United States Tennessee, United States Texas, United States 德国 荷兰 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BI 1701963, Trametinib |
标签
MSS/ MMRp
|
| NCT ID NCT04575922 |
TitleNivolumab+Ipilimumab+RT in MSS mCRC | 阶段
第二阶段
|
Date Added 2020-10-05 |
地点
Massachusetts, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Ipilimumab, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03088150 |
TitleCOLLISION 试验 - 结直肠肝转移：手术与热消融 | 阶段
第三阶段
|
Date Added 2017-03-23 |
地点
荷兰
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
Unknown status
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05213195 |
Title难治性转移性结直肠癌患者的 NKG2D CAR-NK 细胞疗法 | 阶段
第 1 阶段
|
Date Added 2022-01-28 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
NKG2D CAR-NK |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03190941 |
Title给 HLA-A*11:01 患者注射用识别变异 RAS G12V 变异的小鼠 T 细胞受体转导的外周血淋巴细胞 | 阶段
Phase 1, Phase 2
|
Date Added 2017-06-19 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Anti-KRAS G12V mTCR PBL, Cyclophosphamide, Fludarabine, High-dose Aldesleukin |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03785249 |
TitleMRTX849 治疗 KRAS G12C 基因突变癌症患者的 1/2 期研究 KRYSTAL-1 | 阶段
第 1 阶段
|
Date Added 2018-12-24 |
地点
Alabama, United States
Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States 波多黎各 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
afatinib, cetuximab, MRTX849, Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
